No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
Biotech entering a multi-year innovation and M&A wave
The guest argued biotech is on the cusp of a strong innovation cycle, which will drive generalist investor interest and a multi-year wave of M&A activity.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.